Alaunos Therapeutics, Inc.

alaunos.com

What Do They Do?

Develops orally administered small-molecule drug candidates for obesity and related metabolic disorders.

How Do They Make Money?

The company has no product revenue; it receives collaboration revenue from Solasia Pharma K.K., primarily when milestones are achieved.

FY2025 revenue

Who Are Their Customers?

Solasia Pharma K.K. is the counterparty to a collaboration agreement that has generated revenue, primarily through milestone achievements.

Do Revenues Turn Into Profits?

No. It lost $4.2M in FY2025.

Operating income, FY2025

−84500% of revenue

▼ −12% (Loss) vs FY2024 (−$4.8M, −48120%)

Net income, FY2025

−83520% of revenue

▼ −11% (Loss) vs FY2024 (−$4.7M, −46790%)

Free cash flow, FY2025

−59340% of revenue

▼ −40% (Loss) vs FY2024 (−$5M, −49710%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: vs $0 in Q2 FY2025
Net income: ▼ −9% (Loss); vs −$1.1M in Q2 FY2025

Apr 15, 2026 Nasdaq notified Alaunos of a continued-listing equity shortfall Alaunos said it intended to submit a compliance plan and was evaluating actions to regain compliance.

Shrinking. Revenue fell 99% in 4 years, from $400K in FY2021 to $5K in FY2025, about 67% a year.

From cell therapy to metabolic drugs The older report described a clinical-stage oncology business developing engineered T-cell therapies; the latest focuses on preclinical oral small-molecule treatments for obesity and related metabolic disorders.

Who Do They Compete With?

Competes with Novo Nordisk, Eli Lilly, Amgen, Pfizer, Viking Therapeutics, and Structure Therapeutics

Comments